{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T07:01:59Z","timestamp":1789628519555,"version":"build-2803163510"},"reference-count":99,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Clin Oncol"],"DOI":"10.3892\/mco.2026.2971","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T11:19:00Z","timestamp":1786619940000},"page":"1-10","source":"Crossref","is-referenced-by-count":0,"title":["Tumor microenvironment\u2011mediated resistance to immune checkpoint inhibitors in non\u2011small cell lung cancer: Mechanisms, combination strategies and clinical perspectives (Review)"],"prefix":"10.3892","volume":"25","author":[{"given":"Jiange","family":"Mu","sequence":"first","affiliation":[{"name":"School of Clinical Medicine, Changchun University of Chinese Medicine, Changchun, Jilin 130000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Beijing Jishuitan Hospital Affiliated to Capital Medical University, Beijing 100000, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"key20260917090405_b1-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"key20260917090405_b2-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: Epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"key20260917090405_b3-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"key20260917090405_b4-MCO-25-4-02971"},{"issue":"4189","key":"key20260917090405_b5-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13144189","article-title":"Advances in non-small cell lung cancer: Current insights and future directions","volume":"13","author":"Garg","year":"2024","journal-title":"J Clin Med"},{"key":"key20260917090405_b6-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of Pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor Na\u00efve patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"165","key":"key20260917090405_b7-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1073-4","article-title":"EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"key":"key20260917090405_b8-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"key20260917090405_b9-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic Non-small-cell lung cancer With PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20260917090405_b10-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"key20260917090405_b11-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"issue":"52","key":"key20260917090405_b12-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.20517\/cdr.2024.166","article-title":"Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer","volume":"7","author":"Dai","year":"2024","journal-title":"Cancer Drug Resist"},{"key":"key20260917090405_b13-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"key20260917090405_b14-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.tips.2024.04.006","article-title":"Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities","volume":"45","author":"Konen","year":"2024","journal-title":"Trends Pharmacol Sci"},{"key":"key20260917090405_b15-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth","volume":"41","author":"de Visser","year":"2023","journal-title":"Cancer Cell"},{"issue":"7493","key":"key20260917090405_b16-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087493","article-title":"Tumor-associated macrophage subsets: Shaping polarization and targeting","volume":"24","author":"Zhang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"key20260917090405_b17-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"key20260917090405_b18-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-94-007-0782-5_7","article-title":"Expression of macrophage antigens by tumor cells","volume":"714","author":"Shabo","year":"2011","journal-title":"Adv Exp Med Biol"},{"key":"key20260917090405_b19-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","article-title":"A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells","volume":"184","author":"Cheng","year":"2021","journal-title":"Cell"},{"issue":"741305","key":"key20260917090405_b20-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.741305","article-title":"Tumor-Associated macrophages and their functional transformation in the hypoxic tumor microenvironment","volume":"12","author":"He","year":"2021","journal-title":"Front Immunol"},{"key":"key20260917090405_b21-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","article-title":"Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity","volume":"21","author":"Veglia","year":"2021","journal-title":"Nat Rev Immunol"},{"issue":"362","key":"key20260917090405_b22-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00670-9","article-title":"Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"key20260917090405_b23-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression-implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260917090405_b24-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1084\/jem.20101606","article-title":"Sliding set-points of immune responses for therapy of autoimmunity","volume":"207","author":"Hsieh","year":"2010","journal-title":"J Exp Med"},{"issue":"132","key":"key20260917090405_b25-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0449-0","article-title":"Soluble immune checkpoints in cancer: Production, function and biological significance","volume":"6","author":"Gu","year":"2018","journal-title":"J Immunother Cancer"},{"key":"key20260917090405_b26-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/35036374","article-title":"Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis","volume":"2","author":"Bergers","year":"2000","journal-title":"Nat Cell Biol"},{"key":"key20260917090405_b27-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1096\/fj.04-2140fje","article-title":"Contribution of host MMP-2 and MMP-9 to promote tumor vascularization and invasion of malignant keratinocytes","volume":"19","author":"Masson","year":"2005","journal-title":"FASEB J"},{"issue":"2044","key":"key20260917090405_b28-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042044","article-title":"Exploring the molecular tumor microenvironment and translational biomarkers in brain metastases of Non-small-cell lung cancer","volume":"25","author":"Wen","year":"2024","journal-title":"Int J Mol Sci"},{"key":"key20260917090405_b29-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41568-020-0285-7","article-title":"The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy","volume":"20","author":"Bruni","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"key20260917090405_b30-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"key20260917090405_b31-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1111\/imr.12519","article-title":"LAG3 (CD223) as a cancer immunotherapy target","volume":"276","author":"Andrews","year":"2017","journal-title":"Immunol Rev"},{"key":"key20260917090405_b32-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.0105-2896.2010.00903.x","article-title":"TIM genes: A family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity","volume":"235","author":"Freeman","year":"2010","journal-title":"Immunol Rev"},{"issue":"e000957","key":"key20260917090405_b33-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000957","article-title":"TIGIT in cancer immunotherapy","volume":"8","author":"Chauvin","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"699895","key":"key20260917090405_b34-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.699895","article-title":"TIGIT, the next step towards successful combination immune checkpoint therapy in cancer","volume":"12","author":"Ge","year":"2021","journal-title":"Front Immunol"},{"key":"key20260917090405_b35-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J Exp Med"},{"key":"key20260917090405_b36-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1038\/s41586-020-03045-2","article-title":"Metabolic support of tumour-infiltrating regulatory T cells by lactic acid","volume":"591","author":"Watson","year":"2021","journal-title":"Nature"},{"key":"key20260917090405_b37-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1126\/science.aaw7875","article-title":"Vascular regulation of antitumor immunity","volume":"365","author":"Munn","year":"2019","journal-title":"Science"},{"key":"key20260917090405_b38-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1158\/2326-6066.CIR-23-0139","article-title":"Antitumor immune responses in B2M-deficient cancers","volume":"11","author":"Torrejon","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"636568","key":"key20260917090405_b39-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer immune evasion through loss of MHC class I antigen presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol"},{"issue":"1387896","key":"key20260917090405_b40-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1387896","article-title":"Prognostic implications of STK11 with different mutation status and its relationship with tumor-infiltrating immune cells in non-small cell lung cancer","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"key20260917090405_b41-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41423-020-00577-5","article-title":"The cutting-edge progress of immune-checkpoint blockade in lung cancer","volume":"18","author":"Zhou","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"key20260917090405_b42-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"238","DOI":"10.15252\/emmm.201606646","article-title":"The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism","volume":"9","author":"Calvayrac","year":"2017","journal-title":"EMBO Mol Med"},{"key":"key20260917090405_b43-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","article-title":"The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies","volume":"21","author":"Kumagai","year":"2020","journal-title":"Nat Immunol"},{"key":"key20260917090405_b44-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1158\/2326-6066.CIR-20-0196","article-title":"The Gut Microbiome Associates with Immune Checkpoint Inhibition Outcomes in Patients with Advanced Non-Small Cell Lung Cancer","volume":"8","author":"Hakozaki","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"1218386","key":"key20260917090405_b45-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1218386","article-title":"Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: An umbrella review","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"key20260917090405_b46-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"key20260917090405_b47-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"9406","DOI":"10.3390\/curroncol30110681","article-title":"The gut microbiome from a biomarker to a novel therapeutic strategy for immunotherapy response in patients with lung cancer","volume":"30","author":"Duttagupta","year":"2023","journal-title":"Curr Oncol"},{"key":"key20260917090405_b48-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1126\/science.aaz7015","article-title":"Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response","volume":"374","author":"Spencer","year":"2021","journal-title":"Science"},{"issue":"1565","key":"key20260917090405_b49-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041565","article-title":"The role of tumor microenvironment cells in colorectal cancer (CRC) cachexia","volume":"22","author":"Kasprzak","year":"2021","journal-title":"Int J Mol Sci"},{"key":"key20260917090405_b50-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"key20260917090405_b51-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"key20260917090405_b52-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"issue":"77","key":"key20260917090405_b53-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01956-6","article-title":"Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: A real-world comparison","volume":"23","author":"Cheng","year":"2024","journal-title":"Mol Cancer"},{"key":"key20260917090405_b54-MCO-25-4-02971","doi-asserted-by":"crossref","first-page":"9503","DOI":"10.1200\/JCO.2020.38.15_suppl.9503","article-title":"Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE)","volume":"38","author":"Rodriguez-Abreu","year":"2020","journal-title":"J Clin Oncol"},{"key":"key20260917090405_b55-MCO-25-4-02971"},{"key":"key20260917090405_b56-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"e003776","key":"key20260917090405_b57-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003776","article-title":"Phase I\/II study of the LAG-3 inhibitor ieramilimab (LAG525) \u00b1 anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","volume":"10","author":"Sch\u00f6ffski","year":"2022","journal-title":"J Immunother Cancer"},{"key":"key20260917090405_b58-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1002\/cncr.34683","article-title":"Emerging therapeutic strategies for enhancing sensitivity and countering resistance to programmed cell death protein 1 or programmed death-ligand 1 inhibitors in non-small cell lung cancer","volume":"129","author":"Villaruz","year":"2023","journal-title":"Cancer"},{"issue":"10501","key":"key20260917090405_b59-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"key20260917090405_b60-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: Opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260917090405_b61-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.ccell.2014.10.006","article-title":"Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia","volume":"26","author":"Jain","year":"2014","journal-title":"Cancer Cell"},{"key":"key20260917090405_b62-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N Engl J Med"},{"key":"key20260917090405_b63-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S2213-2600(19)30084-0","article-title":"Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): Key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial","volume":"7","author":"Reck","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"12624","key":"key20260917090405_b64-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"issue":"60","key":"key20260917090405_b65-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"key":"key20260917090405_b66-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1001\/jamaoncol.2018.3039","article-title":"Effect of anlotinib as a third-line or further treatment on overall survival of patients with advanced non-small cell lung cancer: The ALTER 0303 phase 3 randomized clinical trial","volume":"4","author":"Han","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20260917090405_b67-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"key20260917090405_b68-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.annonc.2020.03.287","article-title":"Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial","volume":"31","author":"Paz-Ares","year":"2020","journal-title":"Ann Oncol"},{"issue":"939249","key":"key20260917090405_b69-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.939249","article-title":"Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors","volume":"12","author":"Zhang","year":"2022","journal-title":"Front Oncol"},{"issue":"108114","key":"key20260917090405_b70-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108114","article-title":"Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy","volume":"235","author":"Joshi","year":"2022","journal-title":"Pharmacol Ther"},{"key":"key20260917090405_b71-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"4585","DOI":"10.1158\/1078-0432.CCR-15-3101","article-title":"EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in Non-Small cell lung cancer: A retrospective analysis","volume":"22","author":"Gainor","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"S115","key":"key20260917090405_b72-MCO-25-4-02971","article-title":"136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial","volume":"11","author":"Ahn","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20260917090405_b73-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1200\/JCO.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor-resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"key":"key20260917090405_b74-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1158\/2159-8290.CD-21-0226","article-title":"Targeting EGFR Exon 20 insertions in Non-small cell lung cancer: Recent advances and clinical updates","volume":"11","author":"Meador","year":"2021","journal-title":"Cancer Discov"},{"key":"key20260917090405_b75-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.annonc.2024.05.541","article-title":"Amivantamab plus lazertinib versus osimertinib in first-line EGFR-mutant advanced non-small-cell lung cancer with biomarkers of high-risk disease: A secondary analysis from MARIPOSA","volume":"35","author":"Felip","year":"2024","journal-title":"Ann Oncol"},{"issue":"84","key":"key20260917090405_b76-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01304-5","article-title":"Crosstalk among m6A RNA methylation, hypoxia and metabolic reprogramming in TME: From immunosuppressive microenvironment to clinical application","volume":"15","author":"Zhang","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"1753466618794133","key":"key20260917090405_b77-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1177\/1753466618794133","article-title":"New strategies in immunotherapy for lung cancer: Beyond PD-1\/PD-L1","volume":"12","author":"Villanueva","year":"2018","journal-title":"Ther Adv Respir Dis"},{"key":"key20260917090405_b78-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/nrc.2016.77","article-title":"Reprogramming glucose metabolism in cancer: Can it be exploited for cancer therapy?","volume":"16","author":"Hay","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"key20260917090405_b79-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"key20260917090405_b80-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","volume":"8","author":"Ricciuti","year":"2022","journal-title":"JAMA Oncol"},{"key":"key20260917090405_b81-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","article-title":"High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types","volume":"32","author":"McGrail","year":"2021","journal-title":"Ann Oncol"},{"key":"key20260917090405_b82-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J Clin Invest"},{"key":"key20260917090405_b83-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.cels.2023.03.008","article-title":"Deciphering tumor ecosystems at super resolution from spatial transcriptomics with TESLA","volume":"14","author":"Hu","year":"2023","journal-title":"Cell Syst"},{"key":"key20260917090405_b84-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lungcan.2018.09.010","article-title":"Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer","volume":"125","author":"Liu","year":"2018","journal-title":"Lung Cancer"},{"key":"key20260917090405_b85-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","article-title":"Liquid biopsy for advanced NSCLC: A consensus statement from the international association for the study of lung cancer","volume":"16","author":"Rolfo","year":"2021","journal-title":"J Thorac Oncol"},{"issue":"eaau6977","key":"key20260917090405_b86-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1126\/science.aau6977","article-title":"The biology, function, and biomedical applications of exosomes","volume":"367","author":"Kalluri","year":"2020","journal-title":"Science"},{"key":"key20260917090405_b87-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.jtho.2022.09.109","article-title":"IASLC Pathology Committee. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the International Association for the Study of Lung Cancer Pathology Committee","volume":"17","author":"Mino-Kenudson","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"1647807","key":"key20260917090405_b88-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1647807","article-title":"Exploring the carcinogenic potential of bisphenol A in lung adenocarcinoma: Molecular mechanisms, key gene insights, and immune microenvironment impacts","volume":"16","author":"Chen","year":"2025","journal-title":"Front Immunol"},{"issue":"118225","key":"key20260917090405_b89-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2025.118225","article-title":"Assessing the neurotoxic risks of triethyl citrate in daily environmental exposure using network toxicology and molecular docking","volume":"297","author":"Ouyang","year":"2025","journal-title":"Ecotoxicol Environ Saf"},{"issue":"e27151","key":"key20260917090405_b90-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e27151","article-title":"Synergistic role of activated CD4+ memory T cells and CXCL13 in augmenting cancer immunotherapy efficacy","volume":"10","author":"Ouyang","year":"2024","journal-title":"Heliyon"},{"key":"key20260917090405_b91-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/JS9.0000000000001875","article-title":"Artificial intelligence-based multi-modal multi-tasks analysis reveals tumor molecular heterogeneity, predicts preoperative lymph node metastasis and prognosis in papillary thyroid carcinoma: A retrospective study","volume":"111","author":"Yu","year":"2025","journal-title":"Int J Surg"},{"issue":"156841","key":"key20260917090405_b92-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2025.156841","article-title":"Traditional Chinese medicine in cerebral infarction: Integrative strategies and future directions","volume":"143","author":"Ouyang","year":"2025","journal-title":"Phytomedicine"},{"key":"key20260917090405_b93-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jtho.2023.11.018","article-title":"Immune-related toxicity in non-small cell lung cancer: Current state-of-the-art and future directions","volume":"19","author":"O'Leary","year":"2024","journal-title":"J Thorac Oncol"},{"key":"key20260917090405_b94-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"issue":"1415470","key":"key20260917090405_b95-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1415470","article-title":"Immune-related adverse events in patients treated with immunotherapy for locally advanced or metastatic NSCLC in real-world settings: a systematic review and meta-analysis","volume":"14","author":"Pasello","year":"2024","journal-title":"Front Oncol"},{"issue":"686876","key":"key20260917090405_b96-MCO-25-4-02971","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.686876","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors for advanced non-small cell lung cancer: A network meta-analysis of randomized clinical trials","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"key":"key20260917090405_b97-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20260917090405_b98-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","year":"2021","journal-title":"Ann Oncol"},{"key":"key20260917090405_b99-MCO-25-4-02971","doi-asserted-by":"publisher","first-page":"582","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines Insights: Management of immunotherapy-related toxicities, Version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:04:14Z","timestamp":1789625054000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/mco.2026.2971"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":99,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8,13]]}},"URL":"https:\/\/doi.org\/10.3892\/mco.2026.2971","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]}}}